DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD
by Zacks Equity Research
Cooper Companies' latest launch is likely to simplify the insertion process of Paragard IUD, thus making it a more accessible contraceptive choice.
DaVita and Potlatch have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
DaVita and Potlatch are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: DaVita (DVA)
by Shaun Pruitt
Seeing as DaVita's (DVA) growth is also crucial to societal health, its valuation is very intriguing at the moment as the leading provider of kidney care services in the United States.
Centene's Unit Secures New Four-Year Medicaid Contract in Iowa
by Zacks Equity Research
CNC's unit, Iowa Total Care, wins a new contract to provide Medicaid managed care services, enhancing its presence in Iowa and bringing improved health outcomes in the state.
DaVita HealthCare (DVA) Up 13% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Medical Stocks to Hedge Against the September Effect
by Shaun Pruitt
Often sought out for defensive protection amid heightened market volatility, medical stocks may be of interest to investors in September which has historically been the most challenging month for stocks.
DaVita Rallies 44% Year to Date: What's Driving the Stock?
by Zacks Equity Research
DVA's shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.
DaVita HealthCare (DVA) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up
by Zacks Equity Research
CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.
Best Value Stocks to Buy for August 30th
by Zacks Equity Research
RCMT, AIZ and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 30, 2024.
COO Stock Gains on Q3 Earnings & Revenue Beat, Margins Up
by Zacks Equity Research
Cooper Companies' solid segmental results led to an encouraging fiscal third-quarter performance, driving up share prices in after-hours trading.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Analyst Blog Highlights DaVita and Illumina
by Zacks Equity Research
DaVita and Illumina are included in this Analyst Blog.
Zacks Investment Ideas feature highlights: DaVita, Starwood Property and Philip Morris
by Zacks Equity Research
DaVita, Starwood Property and Philip Morris have been highlighted in this Investment Ideas article.
3 Defensive Stocks Outperforming in a Choppy Market (PM, DVA, STWD)
by Ethan Feller
Philip Morris International, Starwood Property Trust and DaVita all show relative strength and top Zacks Ranks
PDCO Stock Falls on Q1 Earnings & Sales Miss, Gross Margin Up Y/Y
by Zacks Equity Research
Patterson Companies' first-quarter fiscal 2025 results reflect the negative impact of a cyberattack on its vendor, Change Healthcare.
Aveanna Stock Rallies 110% in 3 Months: Is It Still Worth Buying?
by Indrajit Bandyopadhyay
AVAH stock has the potential to continue its uptrend on the back of a better payer rate environment and its focus on high-paying customers.
2 Must-Buy Medical Stocks With Strong Momentum
by Nalak Das
Two medical stocks with strong momentum and a favorable Zacks Rank are: DVA, ILMN.
Reasons to Retain Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction through its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition
by Zacks Equity Research
McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.
Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Best Momentum Stock to Buy for August 27th
by Zacks Equity Research
DVA, MRX and AIZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 27, 2024.
Is DaVita (DVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.